Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C

Journal of Neuro-Oncology

Volumn 91, Issue 3, 2009, Pages 271-277

  Chamberlain, Marc C ^a   Johnston, Sandra K ^a   Horn, Alixis ^b   Glantz, Michael J ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Intra CSF liposomal ara C and rituximab; Lymphomatous meningitis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; LIPOSOME; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLERGIC REACTION; ARACHNOIDITIS; ARTICLE; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; LIPOSOMAL DELIVERY; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PALLIATIVE THERAPY; RECURRENT LYMPHOMATOUS MENINGITIS; SINGLE DRUG DOSE; SURVIVAL TIME; SYSTEMIC DISEASE; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTARABINE; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MENINGITIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHOLIPIDS; SURVIVAL ANALYSIS;

EID: 58149470806     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9707-1     Document Type: Article

References (20)

1. Recht L, Straus DJ, Cirrincione C et al (1988) Central nervous system metastases from non-Hodgkin's lymphoma: Treatment and prophylaxis. Am J Med 84:425-435
2. Haioun C, Besson C, Lepage E et al (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 11:685-690
3. Hollender A, Kvaloy S, Lote K et al (2000) Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 36:1762-1768
4. Jahnke K, Thiel E, Martus P et al (2006) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85:45-50
5. Bollen EL, Brouwer RE, Hamers S et al (1997) Central nervous system relapses in non-Hodgkin lymphoma. A single-centre study of 532 patients. Arch Neurol 54:854-859
6. Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1,693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 18:149-157
7. Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11:561-569
8. Hitchens R, Bell D, Woods R et al (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655-1662
9. Glantz M, Jaeckle KA, Chamberlain MC et al (1999) A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116
10. Glantz M, Jaeckle K, Chamberlain MC et al (1999) A randomized trial comparing intrathecal sustained-release ara-C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394-3402
11. Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: A randomized study. Eur J Cancer 40:2726-2733
12. Kaplan EL, Meier P (1958) Nonparametric estimation form incomplete observations. J Am Stat Assoc 53:457-481
13. Guruangan S, Pedros WP, Poussaint TY et al (2008) Phase 1 trial of intrathecal spartaject busulfan in children with neoplastic meningitis; a pediatric brain tumor consortium study (PBTC-004). Clin Cancer Res 12:1540-1546
14. Chamberlain MC, Wei-Tao DD, Groshen S (2006) A Phase II trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer 31(9):2021-2027
15. Rubenstein JL, Coombs D, Rosenberg J et al (2003) Rituximab in CNS lymphoma; targeting the leptomeningeal compartment. Blood 101:466-468
16. Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase 1 study of intraventricular administration of rituximab in patients with recurrent CNS and intra-ocular lymphoma. J Clin Oncol 25(11):1350-1356
17. Glantz MJ, Cole BF, Recht L (1998) High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: Is intrathecal hemotherapy necessary? J Clin Oncol 16(4):1561-1567
18. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (1983) Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1(9):546-551
19. Maria BL, Boss TF, Guzman GA, Gouveia WA, White CA, Strauss MJ (1996) Cost of treating leptomeningeal metastases with intrathecal Depofoam TM encapsulated cytarabine. Presented at 1996 American society of clinical oncologists annual meeting, 18-21 May 1996, Philadelphia, Pennsylvania. Proc Am Soc Clin Oncol 15:160 (abstract 305)
20. Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 18:149-157